15 September 2014: Clinical Research
The Incidence and Risk Factors of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants in Turkey
Ali Riza Cenk Celebi ABCDEF , Ikbal Seza Petricli AB , Emre Hekimoglu AB , Nihal Demirel A , Ahmet Yagmur Bas A
DOI: 10.12659/MSM.892262
Med Sci Monit 2014; 20:1647-1653
Abstract
BACKGROUND: The aim of this study was to identify the incidence of severe retinopathy of prematurity (ROP) requiring laser treatment and the overall incidence of ROP in extremely low birth weight (ELBW) infants, and to evaluate the associated risk factors for developing severe ROP in ELBW infants in Turkey.
MATERIAL AND METHODS: This retrospective, case-control, tertiary care-hospital based study included 235 ELBW infants screened for ROP. The incidence of the onset of ROP and severe ROP requiring laser treatment were assessed. The relationship between various clinical risk factors, and the development of severe ROP and onset of ROP were analyzed using univariate analysis and multivariate logistic regression analysis.
RESULTS: The overall incidence of any stage ROP and severe ROP requiring laser treatment in ELBW infants was 75.5% and 38.7%, respectively. Severe ROP requiring laser treatment in ELBW infants was significantly associated with various independent risk factors, including blood transfusion (P=0.002), gestational age at birth (P<0.001), ges- tational weight at birth (P=0.001), culture-proven sepsis (P=0.047).
CONCLUSIONS: The severity of ROP may increase as weight at birth and gestational age at birth decrease, and in those with culture-proven sepsis as well as in those that receive blood transfusion. Clinicians should be aware of the presence of these risk factors when treating ELBW premature infants. Early detection and prevention of sepsis and reducing the number of blood transfusions may decrease the incidence of severe ROP requiring laser treatment.
Keywords: Gestational Age, Incidence, Infant, Extremely Low Birth Weight - physiology, Infant, Newborn, Logistic Models, Multivariate Analysis, Retinopathy of Prematurity - epidemiology, Risk Factors, Turkey - epidemiology
Background
Retinopathy of prematurity (ROP) is a vasoproliferative disease of the retina that affects preterm neonates and is thought to be mediated by alterations in insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) [1]. ROP is one of the major causes of avoidable childhood blindness in developed and developing countries. Approximately 50 000 children worldwide have ROP-related blindness [2]. The increase in survival rates in extremely low birth weight (ELBW) infants due to improvements in neonatal intensive care has resulted in an increased risk of developing ROP [3]. However, some studies report that improvements in neonatal intensive care have resulted in a decrease in the incidence of ROP [4,5]. Nonetheless, it is known that ROP develops most frequently and most severely in ELBW infants [6].
Recent studies report many systemic risk factors (respiratory distress syndrome, sepsis, necrotizing enterocolitis, intraventricular hemorrhage, and blood transfusion for neonatal severe anemia) associated with ROP [7–9]. The probable cause of the severity of ROP in ELBW infants could be associated with the risk factors stated above. The aim of the present study was to determine the incidence of severe ROP requiring laser treatment and the overall incidence of ROP, and to evaluate the risk factors for developing severe ROP requiring laser treatment in ELBW infants in Turkey.
Material and Methods
STATISTICAL ANALYSIS:
Statistical analysis was performed using SPSS v.16.0 for Windows (SPSS, Inc. Chicago, IL, USA). Continuous variables are presented as mean ± SD; categorical variables are expressed as number and percentage. The Kolmogorov-Smirnov test was used to analyze the normality of data distribution. Descriptive statistics, such as frequencies of NEC, PDA, IVH, blood transfusion, RDS, and sepsis, were analyzed. Mean gestational weight and gestational age at birth were compared between groups using Kruskal-Wallis analysis. The chi-square test was used to compare categorical data related to clinical outcome. Univariate analysis was conducted to assess other potential risk factors for stage 3 ROP requiring laser treatment, such as sex, sepsis, blood transfusions, IVH, PDA, and NEC. To control for all of the variables and estimate the independent significant risk factors associated with stage 3 ROP requiring laser treatment, the factors were entered into a logistic regression multivariate analysis using a stepwise model. The level of statistical significance was set at P<0.05. The adjusted odds ratio (OR) and 95% confidence interval (CI) for each possible risk factor were calculated.
Results
In total, 235 infants weighing <1000 g were included in the study. Mean birth weight and mean gestational age were 858.31±107.45 g (range: 570–1000 g) and 27.08±1.99 weeks (range: 23–33 weeks), respectively. In all, 129 of the infants were female (54.9%) and 106 were male (45.1%). Among the patients, 48 (20.4%) developed culture-proven sepsis, 147 (62.5%) received surfactant and/or required oxygen therapy due to RDS, 12 (5.1%) developed IVH, 11 (4.7%) had NEC, 54 (22.9%) developed PDA, and 53 (22.5%) received blood transfusions. All baseline characteristics and associated systemic findings in the study population are summarized in Table 1.
In overall, 62 (26.4%) patients did not develop any stage of ROP. Mean birth weight and gestational age in the infants without ROP were 915.56±81.27 g (range: 600–1000 g) and 28.34±1.91 weeks (range: 25–33 weeks), respectively; the male-to-female ratio was 0.82 (28/34).
Among the patients developing any stage of ROP, 37.02% (n=87) did not require laser treatment. In total, 61 (25.9%) patients developed stage 1 ROP and 26 (11.06%) developed stage 2 ROP. Mean birth weight and gestational age in the ROP patients that did not require laser treatment were 862.87±101.24 g (range: 600–1000 g) and 27.06±1.96 weeks (range: 23–33), respectively, and the male-to-female ratio was 0.64 (34/53).
There were 86 patients (36.6%) that received laser treatment due to severe ROP or type 1 ROP. Mean birth weight and gestational age in these patients were 816.33±110.68 g (range: 570–1000 g) and 26.28±1.65 weeks (range: 23–32), respectively, and the male-to-female ratio was 1.04 (44/42). There were 21 patients with aggressive posterior ROP, of which 3 had diode laser treatment and progressed to stage 4 ROP. These 3 patients had vitreoretinal surgery. Other laser-treated eyes with signs of severe ROP showed disease regression during the first week and the regression was almost complete at 1 month after the laser therapy. The differences between number of ROP distributions, mean gestational weight, and mean gestational age at birth in the 3 groups were statistically significant (Kruskall- Wallis Analysis P<0.05). The number and percentage of patients without ROP, and those with ROP not requiring and received laser, and their gender distribution and associated systemic findings are shown in Table 2. Table 3 summarizes the mean gestational age and mean gestational weight in the patients without ROP, those with ROP not requiring and requiring laser treatment, and the entire study population.
According to univariate analysis, the only significant risk factor for the presence of any stage ROP in ELBW infants was gestational age at birth (P=0.046), but the main risk factors for ROP requiring laser treatment were low gestational age at birth (P=0.008), low gestational weight at birth (P=0.011), culture-proven sepsis (P=0.017), and blood product transfusion (P=0.0001). The other associated systemic findings, including the presence of NEC (P=0.38), presence of PDA (P=0.33), and presence of RDS (P=0.35) and any stage IVH (P=0.43), were not associated with severe ROP. Univariate analysis showed that there was a significant relationship between ROP requiring laser treatment, and low gestational age, low gestational weight, sepsis, and blood transfusions. These risk factors were entered into multivariate logistic regression analysis via the stepwise (likelihood ratio) method, in which these 4 variables (low gestational age, low gestational weight, sepsis, and blood transfusions) were identified as weak (according to low ORs) but statistically significant (p<0.05) independent risk factors for severe ROP according to the P values and correlation based on adjusted ORs (Table 4). A strong association was observed between blood transfusion and severity of ROP (adjusted OR: 2.165). Gestational age at birth (adjusted OR: 1.410; 95% CI: 1.175–1.694), gestational weight at birth (adjusted OR: 1.115; 95% CI: 1.112–1.118), culture-proven sepsis (adjusted OR: 0.464; 95% CI: 0.218–0.989) were weak (due to low ORs) but statistically significant (p<0.05) factors predictive of severe ROP (Table 4).
Discussion
According to earlier studies, the number of extremely premature infants that survive has been increasing as neonatal care improves [13–16]. It has also been reported that extremely premature infants have a higher risk of developing severe ROP requiring treatment than do more mature infants [8,17–19]. The Early Treatment for Retinopathy of Prematurity (ETROP) study reported that the incidence of ROP was 82.5% in infants with a birth weight <1000 g, and that treatment was required in 92.4% of infants that weighed <1000 g [15]. According to the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) study, ≥81.6% infants that weighed <1000 g at birth developed ROP [20]. Kumar et al. reported that 32.8% of infants with a birth weight <1000 g had ROP [21]. Lorenz et al. noted ROP in 62.1% of infants with a birth weight <1000 g [22]. A multicenter study by Zin et al. reported that 61.9% of infants with a birth weight <1000 g had severe ROP [23] and Choo et al. found that 58.6% of infants weighing <1000 g at birth developed ROP [24]. A recent study from China reported 64% of infants with a birth weight <1000 g developed any stage ROP [25]. In the present study, 73.6% of infants had ROP, which is similar to the rates reported by other Turkish referral centers of 70.7% [26] and 75.6% [27], but lower than that in extremely premature Japanese infants (86.1%) [28].
The rate of type 1 ROP requiring laser treatment among 235 ELBW infants in the present study was 36.6%; only 1 study (by Hiraoka et al.) reported a higher percentage of ELBW infants with severe ROP requiring laser treatment (41%) [28]. The incidence of type 1 ROP in ELBW infants was reported as 36.4% by Gharaibeh et al. [29] and Wani et al. [30], which is similar to the rate in the present study. Choo et al. reported that 32.9% of ELBW infants reached a stage of ROP requiring laser treatment [24]. An earlier Turkish retrospective cohort study observed that 30.2% of ELBW infants who had advanced ROP required laser treatment [26]. Fortes et al. reported that 48.9% of ELBW infants in southern Brazil developed threshold ROP requiring laser treatment [19]; however, a study conducted in China [31] reported that the incidence of ROP requiring laser treatment was 28.6%, in contrast to 28.7% in a study of ELBW infants conducted in the USA [32]. A Canadian study reported that the overall incidence of stage ≥3 ROP in ELBW infants was 17.3% [6]. The lowest incidence of ROP requiring laser treatment in ELBW infants was reported from Brazil (12.7%) [33]. The variation in the reported incidence of severe ROP in the literature is due to numerous factors such as low birth weight (BW), low gestational age (GA), sex, presence of respiratory distress syndrome (RDS), presence of blood culture-proven sepsis, presence of necrotizing enterocolitis (NEC), presence of intraventricular hemorrhage (IVH), and presence of patent ductus arteriosus (PDA) [34]. Also, we think the high incidence of severe ROP in the present study was primarily due to the fact it was conducted in a tertiary referral center that treats ROP patients requiring laser treatment from all over Turkey, and that most of the patients that admitted to our clinic were sick infants and at high-risk for developing severe ROP.
In the present study, low gestational age at birth was a significant risk factor for developing any stage of ROP, according to univariate analysis. Mean gestational age at birth was 28.34±1.91 weeks in the infants without ROP
Univariate analysis and multivariate logistic regression analysis showed that various systemic risk factors, such as the presence of culture-proven sepsis and blood transfusion, were strongly correlated with the development of severe ROP in the present study. Previous reports on very low birth weight infants reported ≥1 of these risk factors, but the present study is the first to report the pathogenic role of these factors in ELBW infants; clinicians must be aware of the importance of these risk factors in ELBW infants and that they can result in severe ROP [44].
Araz et al. reported that there was a strong association between the presence of ROP (as well as severe ROP) and sepsis [45]. Weintraub et al. noted that sepsis increases the risk of developing ROP 12-fold; they hypothesized that sepsis might increase oxygen demand and interfere with oxygen tension, which might increase retinal ischemia, resulting in ROP [46]. In the present study sepsis was an important and significant predictor of developing severe ROP.
Blood transfusion was the most important significant associated risk factor for developing severe ROP in the present study. Earlier studies have reported that blood transfusion is a significant risk factor for the development of threshold disease [42,47]. Weintraub et al. reported that blood transfusion may be considered a clinical marker for the development of stage ≥3 ROP; they reported that the incidence of stage 3 ROP was 14-fold higher in their neonates that received blood transfusions, and posited that it might have been because the high oxygen concentration of the transfused blood may have had toxic effects on the immature peripheral retinal vessels. They also found that a reduction in blood transfusions led to a reduction the incidence of severe ROP [46].
Conclusions
In the present study, the severity of ROP was inversely correlated with birth weight and gestational age at birth, and positively correlated with culture-proven sepsis and blood transfusion. Clinicians should be aware of the presence of these risk factors when treating premature infants. Early detection and prevention of sepsis and reducing the number of blood transfusions may decrease the incidence of severe ROP requiring laser treatment. The identification of other risk factors that might be associated with the severity of ROP warrants further investigation. Additional analysis of the risk factors for severe ROP will improve our understanding and ability to predict the development of severe ROP in extremely premature infants.
References
1. Smith LE, Pathogenesis of retinopathy of prematurity: Growth Horm IGF Res, 2004; 14; 140-44
2. Gilbert C, Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control: Early Hum Dev, 2008; 84; 77-82, pmid: 18234457
3. Valentine PH, Jackson JC, Kalina RE, Woodrum DE, Increased survival of low birth weight infants: impact on the incidence of retinopathy of prematurity: Pediatrics, 1989; 84; 442-45, pmid: 2788864
4. Bullard SR, Donahue SP, Feman SS, The decreasing incidence and severity of retinopathy of prematurity: J AAPOS, 1999; 3; 46-52, pmid: 10071901
5. Chiang MF, Arons RR, Flynn JT, Starren JB, Incidence of retinopathy of prematurity from 1996 to 2000: analysis of a comprehensive New York state patient database: Ophthalmology, 2004; 111; 1317-25, pmid: 15234131
6. Isaza G, Arora S, Incidence and severity of retinopathy of prematurity in extremely premature infants: Can J Ophthalmol, 2012; 47; 296-300, pmid: 22687311
7. Ebrahim M, Ahmad RS, Mohammad M, Incidence and risk factors of retinopathy of prematurity in Babol, North of Iran: Ophthalmic Epidemiol, 2010; 17; 166-70, pmid: 20455847
8. Fortes Filho JB, Eckert GU, The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP): Graefes Arch Clin Exp Ophthalmol, 2010; 248; 893-900, pmid: 20016911
9. Wani VB, Kumar N, Sabti K, Results of screening for retinopathy of prematurity in a large nursery in Kuwait: Incidence and risk factors: Indian J Ophthalmol, 2010; 58; 204-8, pmid: 20413922
10. International Committee for the Classification of Retinopathy of Prematurity, The International Classification of Retinopathy of Prematurity revisited: Arch Ophthalmol, 2005; 123; 991-99, pmid: 16009843
11. Fierson WMAmerican Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists, Screening examination of premature infants for retinopathy of prematurity: Pediatrics, 2013; 131; 189-95, pmid: 23277315
12. Early Treatment for Retinopathy Of Prematurity Cooperative Group, Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial: Arch Ophthalmol, 2003; 121; 1684-94, pmid: 14662586
13. Markestad T, Kaaresen PI, Ronnestad A, Early death, morbidity, and need of treatment among extremely premature infants: Pediatrics, 2005; 115; 1289-98, pmid: 15867037
14. Ells A, Hicks M, Fielden M, Ingram A, Severe retinopathy of prematurity: longitudinal observation of disease and screening implications: Eye, 2005; 19; 138-44, pmid: 15218516
15. Good WV, Hardy RJ, Dobson V, The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study: Pediatrics, 2005; 116; 15-23, pmid: 15995025
16. Fielder AR, Time for a fresh look at ROP screening: Eye, 2003; 17; 117-18, pmid: 12640393
17. Reynolds JD, Dobson V, Quinn GE, Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies: Arch Ophthalmol, 2002; 120; 1470-76, pmid: 12427059
18. Austeng D, Kallen KB, Ewald UW, Incidence of retinopathy of prematurity in infants born before 27 weeks’ gestation in Sweden: Arch Ophthalmol, 2009; 127; 1315-19, pmid: 19822848
19. Fortes Filho JB, Eckert GU, Procianoy L, Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil: Eye, 2009; 23; 25-30, pmid: 17618242
20. Cryotherapy for Retinopathy of Prematurity Cooperative Group, Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results: Arch Ophthalmol, 1988; 106; 471-79, pmid: 2895630
21. Kumar P, Sankar MJ, Deorari A, Risk factors for severe retinopathy of prematurity in preterm low birth weight neonates: Indian J Pediatr, 2011; 78; 812-16, pmid: 21340729
22. Lorenz B, Spasovska K, Elflein H, Schneider N, Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study: Graefes Arch Clin Exp Ophthalmol, 2009; 247; 1251-62, pmid: 19462177
23. Zin AA, Moreira ME, Bunce C, Retinopathy of prematurity in 7 neonatal units in Rio de Janeiro: screening criteria and workload implications: Pediatrics, 2010; 126; 410-17
24. Choo MM, Martin FJ, Theam LC, U-Theng C, Retinopathy of prematurity in extremely low birth weight infants in Malaysia: J AAPOS, 2009; 13; 446-49, pmid: 19840721
25. Li Q, Yin ZQ, Chen L, Incidence of Retinopathy of Prematurity in Southwestern China and Analysis of Risk Factors: Med Sci Monit, 2014; 20; 1442-51, pmid: 25124335
26. Demir S, Sayin O, Aygun C, Retinopathy of prematurity in extremely low birth weight infants in Turkey: J Pediatr Ophthalmol Strabismus, 2013; 50; 229-33, pmid: 23521029
27. Alpay A, Ugurbas SH, Incidence and risk factors for retinopathy of prematurity in the West Black Sea region, Turkey: Turk J Pediatr, 2012; 54; 113-18, pmid: 22734296
28. Hiraoka M, Watanabe T, Kawakami T, Retinopathy of prematurity in extremely low birth weight infants: a Tokyo multicenter study: Nihon Ganka Gakkai Zasshi, 2004; 108; 600-5, pmid: 15559312
29. Gharaibeh A, Khassawneh M, Khriesat W, Adopting Western Retinopathy of Prematurity Screening Programs in Eastern Countries, are we Screening Properly?: Middle East Afr J Ophthalmol, 2011; 18; 209-13, pmid: 21887075
30. Wani VB, Uboweja AK, Gani M, Type I retinopathy of prematurity in infants with birth weight less than 1251 g: incidence and risk factors for its development in a nursery in Kuwait: Middle East Afr J Ophthalmol, 2013; 20; 66-71, pmid: 23580855
31. Chen Y, Li XX, Yin H, Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing, China: Br J Ophthalmol, 2008; 92; 326-30, pmid: 18303154
32. Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM, Incidence of retinopathy of prematurity in the United States: 1997 through 2005: Am J Ophthalmol, 2009; 148; 451-58, pmid: 19541285
33. Fortes Filho JB, Borges Fortes BG, Tartarella MB, Procianoy RS, Incidence and Main Risk Factors for Severe Retinopathy of Prematurity in Infants Weighing Less Than 1000 Grams in Brazil: J Trop Pediatr, 2013; 59; 502-6, pmid: 23771954
34. Darlow BA, Hutchinson JL, Simpson JM, Variation in rates of severe retinopathy of prematurity among neonatal intensive care units in the Australian and New Zealand Neonatal Network: Br J Ophthalmol, 2005; 89; 1592-96, pmid: 16299138
35. Teed RG, Saunders RA, Retinopathy of prematurity in extremely premature infants: J AAPOS, 2009; 13; 370-73, pmid: 19683188
36. Dammann O, Inflammation and retinopathy of prematurity: Acta Paediatr, 2010; 99; 975-77, pmid: 20412106
37. Dammann O, Brinkhaus MJ, Bartels DB, Immaturity, perinatal inflammation, and retinopathy of prematurity: a multi-hit hypothesis: Early Hum Dev, 2009; 85; 325-29, pmid: 19217727
38. Hussain N, Clive J, Bhandari V, Current incidence of retinopathy of prematurity, 1989–1997: Pediatrics, 1999; 104; e26, pmid: 10469809
39. Brown BA, Thach AB, Song JC, Retinopathy of prematurity: evaluation of risk factors: Int Ophthalmol, 1998; 22; 279-83, pmid: 10826544
40. Seiberth V, Linderkamp O, Risk factors in retinopathy of prematurity. a multivariate statistical analysis: Ophthalmologica, 2000; 214; 131-35, pmid: 10720918
41. Bassiouny MR, Risk factors associated with retinopathy of prematurity: a study from Oman: J Trop Pediatr, 1996; 42; 355-58, pmid: 9009563
42. Akkoyun I, Oto S, Yilmaz G, Risk factors in the development of mild and severe retinopathy of prematurity: J AAPOS, 2006; 10; 449-53, pmid: 17070481
43. Allegaert K, Vanhole C, Casteels I, Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity: J AAPOS, 2003; 7; 34-37, pmid: 12690367
44. Shah VA, Yeo CL, Ling YL, Ho LY, Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore: Ann Acad Med Singapore, 2005; 34; 169-78, pmid: 15827664
45. Araz-Ersan B, Kir N, Akarcay K, Epidemiological analysis of retinopathy of prematurity in a referral centre in Turkey: Br J Ophthalmol, 2013; 97; 15-17, pmid: 23125061
46. Weintraub Z, Carmi N, Elouti H, Rumelt S, The association between stage 3 or higher retinopathy of prematurity and other disorders of prematurity: Can J Ophthalmol, 2011; 46; 419-24, pmid: 21995985
47. Allegaert K, de Coen K, Devlieger HEpiBel Study Group, Threshold retinopathy at threshold of viability: the EpiBel study: Br J Ophthalmol, 2004; 88; 239-42, pmid: 14736783
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






